Pharmacia & Upjohn's Fragmin reduces MI risk by 68% in patients with unstable angina -- AHA.T&G-15

Executive Summary

PHARMACIA's FRAGMIN REDUCES RISK OF MYOCARDIAL INFARCTION BY 68% in patients with unstable coronary artery disease or non-Q-wave MI after six days of acute treatment, according to a Swedish study presented at the American Heart Association's 68th Scientific Sessions in Anaheim, Calif. Observations taken after 40 days of treatment with the low molecular weight heparin (dalteparin sodium) also indicate a reduction in death and MI, with significant reductions found in a subgroup analysis for patients with non-Q-wave MI and for non-smokers. Fragmin recently was launched in the U.S. by Pharmacia & Upjohn for deep vein thrombosis prophylaxis in abdominal surgery patients.